New Daily Pill Offers Hope for Resistant HIV Patients

For decades, older HIV patients have been asking their doctors the same heartbreaking question: Why can't I have just one pill like everyone else?

Now, they finally have an answer. A new single daily pill has proven just as effective as the complex multi-drug regimens that tens of thousands of HIV patients must take each day.

Dr. Chloe Orkin at Queen Mary University of London says many of her patients have been stuck taking multiple pills several times daily for years. These are often people diagnosed during the early AIDS epidemic in the 1980s and 90s, when less effective drugs led to medication resistance.

"Science has moved on for everyone else except for them," Orkin explains. "They're like a forgotten population."

While most of the world's 40 million HIV patients can already take a single daily pill or injections every two months, these options don't work for patients with drug resistance. The complex regimens they require come with logistical challenges, uncomfortable side effects like diarrhea, and problematic interactions with other medications.

The new pill, made by Gilead Sciences, combines two HIV drugs into one tablet smaller than a multivitamin. Research published in The Lancet tested it on 550 HIV patients currently on complex treatments.

"The drug worked just as well as the complex regimen," says Orkin, who led the study across more than 90 sites worldwide. Another study presented this week found the pill matches the effectiveness of Biktarvy, one of the most widely prescribed HIV treatments in America.

The Ripple Effect

The impact extends far beyond simplifying pill bottles. Dr. Linda-Gail Bekker, who directs the Desmond Tutu HIV Center in South Africa, says when people take medications for life, simplification helps them stick with treatment.

That consistency prevents HIV from spreading, since patients on medication drop their viral load low enough that they cannot transmit the virus. As more people stay on treatment, entire communities become safer.

Plus, new drug combinations help stay ahead of the constantly mutating HIV virus. "We can't stop," Bekker warns, pointing to how tuberculosis became extremely drug-resistant when innovation stalled.

Gilead Sciences plans to file for FDA approval soon, with a potential launch in the second half of 2025. Bekker notes the HIV community has successfully advocated for affordable access in lower-income countries before, where most of the global burden remains.

After a tough year of international aid cuts disrupting HIV care systems, Bekker says this news brings much-needed hope to the field and patients who've waited far too long.